<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449553</url>
  </required_header>
  <id_info>
    <org_study_id>H6E-CP-GLAR</org_study_id>
    <secondary_id>U1111-1114-2473</secondary_id>
    <nct_id>NCT00449553</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.</brief_title>
  <official_title>A Prospective Study of Associations of Changes in HbA1C and Fasting Blood Lipids Due to Treatment With Pioglitazone for 6 Months and Genetic Polymorphism's in PPAR-gamma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood
      lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma
      receptor after 6 months of pioglitazone, once daily (QD), treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metabolic control in type 2 diabetes mellitus can be measured by means of glycosylated
      hemoglobin. A low value glycosylated hemoglobin indicates a good metabolic control, and has
      been shown to be associated with a better prognosis regarding diabetic complications. Type 2
      diabetes is a disease with a profound genetic component. Peroxisome proliferator-activated
      receptor gamma is a transcription factor implicated in adipocyte differentiation, lipid and
      glucose metabolism. Peroxisome proliferator-activated receptor alfa is a transcription factor
      implicated in lipid oxidation and gluconeogenesis and is present in liver, kidney, heart,
      skeletal muscle and adipose tissue.

      Pioglitazone is a thiazolidinedione that targets nuclear peroxisomal proliferator activated
      receptors, members of the super family of ligand activated transcription factors.
      Specifically, thiazolidinediones bind to the peroxisome proliferator-activated receptor gamma
      and affect transcription factors that influence expression of genes responsible for the
      production of proteins important in carbohydrate and lipoprotein metabolism. These include
      increases in glucose transporters 1 and 4 resulting in enhanced peripheral glucose
      utilization by fat and skeletal muscle.

      This is a pharmacoepidemiological study to evaluate whether the individual genotype of the
      patients have any influence on the efficacy of pioglitazone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Laboratory Tests (alanine transaminase, hematocrit and hemoglobin).</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Weight.</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of treatment responders defined as a patient with 0.6% decrease in HbA1C from baseline visit to final visit or accomplishment of a HbA1c value at or below 6.5%.</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in beta-cell function (Homeostasis model assessment).</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin resistance (Homeostasis model assessment).</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting lipoproteins (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol and triglycerides).</measure>
    <time_frame>End of Treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">326</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 15 mg QD + Sulphonylurea</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg QD + Sulphonylurea</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 15 mg QD + Metformin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg QD + Metformin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and sulphonylurea</intervention_name>
    <description>Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.</description>
    <arm_group_label>Pioglitazone 15 mg QD + Sulphonylurea</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and sulphonylurea</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.</description>
    <arm_group_label>Pioglitazone 30 mg QD + Sulphonylurea</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and metformin</intervention_name>
    <description>Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.</description>
    <arm_group_label>Pioglitazone 15 mg QD + Metformin</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and metformin</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.</description>
    <arm_group_label>Pioglitazone 30 mg QD + Metformin</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood for DNA-analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving pioglitazone therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfills all requirements for treatment with pioglitazone.

          -  Willing to start treatment with pioglitazone.

        Exclusion Criteria:

          -  Has previously participated in this study.

          -  Is currently taking or have taken oral antidiabetic medications other than
             sulfonylurea or metformin within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP Clinical Science Strategy</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Global Research and Developmnet Center Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOS® Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

